Results 41 to 50 of about 36,463 (268)

Metabolic fate of drugs of abuse and new psychoactive substances: A pilot study on a novel workflow using a zebrafish embryo model combined with human microdosing

British Journal of Clinical Pharmacology, EarlyView.
Aim The aim of this study was to develop a novel workflow to identify human urine biomarkers for drugs of abuse and new psychoactive substances. Metabolites of amphetamine, cocaine, LSD, MDMA, methamphetamine, THC, MDMB‐CHMICA, and MDPPP were first identified in a zebrafish embryo (ZE) metabolism study followed by comparison to most abundant human ...
Simon K. Wellenberg, Tanja M. Gampfer, Lea Wagmann, Philip Schippers, Jennifer Herrmann, Rolf Müller, Folker Westphal, Markus R. Meyer   +7 more
wiley   +1 more source

Does Cannabis Use Contribute to Schizophrenia? A Causation Analysis Based on Epidemiological Evidence

Biomolecules
Cannabis abuse has been linked to acute psychotic symptoms as well as to the development of schizophrenia. Although the association has been well described, causation has not yet been investigated.
Sepehr Pourebrahim, Tooba Ahmad, Elisabeth Rottmann, Johannes Schulze, Bertram Scheller   +4 more
doaj   +1 more source

Network-Based Pharmacology Study Reveals Protein Targets for Medical Benefits and Harms of Cannabinoids in Humans

Applied Sciences, 2022
This network-based pharmacology study intends to uncover the underlying mechanisms of cannabis leading to a therapeutic benefit and the pathogenesis for a wide range of diseases claimed to benefit from or be caused by the use of the cannabis plant ...
Xingyu Li, Amit Madhukar Kudke, Felix Joseph Nepveux V, Yan Xu   +3 more
doaj   +1 more source

Lasting effects of repeated ∆9‐tetrahydrocannabinol vapour inhalation during adolescence in male and female rats

British Journal of Pharmacology, 2019
Adolescents are regularly exposed to ∆9‐tetrahydrocannabinol (THC) via smoking and, more recently, vaping cannabis extracts. Growing legalization of cannabis for medical and recreational purposes, combined with decreasing perceptions of harm, makes it ...
Jacques D. Nguyen, K. Creehan, T. Kerr, M. Taffe   +3 more
semanticscholar   +1 more source

Low‐dose cannabidiol increases plasma concentrations of amitriptyline: A clinical drug–drug interaction study

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims Cannabidiol (CBD), the main non‐intoxicating compound from the cannabis plant, is regularly used by patients with chronic pain who also take analgesics. CBD has previously been shown to inhibit CYP‐mediated drug metabolism. This study aimed to characterize the potential pharmacokinetic interaction of CBD with amitriptyline and tramadol ...
Andriy A. Gorbenko, Titiaan E. Post, Pamela K. Strugala, Erica S. Klaassen, Linda E. Klumpers, Saco J. de Visser, Cristina Sempio, Jost Klawitter, Jules A. A. C. Heuberger, Geert J. Groeneveld   +9 more
wiley   +1 more source

Quantification and prediction of human fetal (-)-Δ9-tetrahydrocannabinol/(±)-11-OH-Δ9-tetrahydrocannabinol exposure during pregnancy to inform fetal cannabis toxicity

Nature Communications
Prenatal cannabis use is associated with neurodevelopmental deficits, likely due to exposure to the psychoactive cannabinoid, (-)-Δ9-tetrahydrocannabinol, and its active metabolite, (±)-11-OH-Δ9-tetrahydrocannabinol.
Aditya R. Kumar, Lyndsey S. Benson, Erica M. Wymore, Jocelyn E. Phipers, Jennifer C. Dempsey, Lucinda A. Cort, Jashvant D. Unadkat   +6 more
doaj   +1 more source

Cannabis and Anxiety: A Critical Review

Medical Cannabis and Cannabinoids
Introduction: Cannabis has been reported to have both anxiogenic and anxiolytic effects. Habitual cannabis use has been associated with anxiety disorders (AD).
Alexander Beletsky, Cherry Liu, Bryson Lochte, Nebiyou Samuel, Igor Grant   +4 more
doaj   +1 more source

Priority areas for cannabis and cannabinoid product research in South Africa

African Journal of Primary Health Care & Family Medicine, 2018
No abstract available.
Tanya N. Augustine, Carel J. Cairns, Sean Chetty, Lisa G. Dannatt, Nadine Gravett, Glenda Grey, Gerhard Grobler, Zukiswa Jafta, Peter Kamerman, John Lopes, Motlalepula G. Matsabisa, Pierre Mugabo, Michelle Mulder, Charles Parry, Solomon Rataemane, Nandi Siegfried, Vanessa Steenkamp, Eileen Thomas, Richard van Zyl-Smit   +18 more
doaj   +1 more source

Major Phytocannabinoids and Their Related Compounds: Should We Only Search for Drugs That Act on Cannabinoid Receptors?

Pharmaceutics, 2021
The most important discoveries in pharmacology, such as certain classes of analgesics or chemotherapeutics, started from natural extracts which have been found to have effects in traditional medicine.
Leontina Elena Filipiuc, Daniela Carmen Ababei, Teodora Alexa-Stratulat, Cosmin Vasilica Pricope, Veronica Bild, Raluca Stefanescu, Gabriela Dumitrita Stanciu, Bogdan-Ionel Tamba   +7 more
doaj   +1 more source

Cannabinoids and drug–drug pharmacokinetic interactions: Deciphering the risks

British Journal of Clinical Pharmacology, EarlyView.
The relationship between cannabinoids and mental health has become a major focus of scientific inquiry and public discourse. Cannabinoids are diverse chemical compounds from the Cannabis species that have been explored for their therapeutic applications in treating chronic pain, psychiatric and neurological conditions, such as depression, schizophrenia,
Paraskevi Papakyriakopoulou, Georgia Valsami, Georgios Ismailos   +2 more
wiley   +1 more source